[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Epiliquid Holding, Inc\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":96},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,75],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100604345","hepatocellular-carcinoma-identification-using-delta-hld-100604345",false,"NCT07148310","Hepatocellular Carcinoma Identification Using Delta-HLD","Proof-of-Concept Case-Control Study for Hepatocellular Carcinoma Identification Using Delta-HLD Technology (HIDE)","HIDE","Inclusion Criteria:\n\n* Histologically confirmed HCC (cases) or clinically confirmed liver cirrhosis without HCC (controls)\n* Willing and able to provide informed consent\n* Available paired plasma and liver tissue sample\n\nExclusion Criteria:\n\n* Other active cancers\n* Prior liver transplantation\n* Known hereditary cancer syndromes\n* Recent chemotherapy or antiviral treatment (\\\u003C3 months)","ALL","18 Years","75 Years",{"count":21,"type":22},200,"ESTIMATED","OBSERVATIONAL","HIDE (Hepatocellular Carcinoma Identification via Delta-HLD) is a proof-of-concept case-control study designed to evaluate the performance of delta-HLD, Epiliquid's proprietary liquid biopsy technology, in detecting hepatocellular carcinoma (HCC). The study includes both plasma and tissue samples to assess biomarker concordance and evaluate diagnostic sensitivity and specificity using tumor-specific methylation markers detected by PCR.",[26],"Hepato Cellular Carcinoma (HCC)",[28,29,30,31,32,33,34],"Hepatocellular carcinoma","Epigenetics","Liquid Biopsy","cfDNA","Biomarker","Methylation","PCR","RECRUITING","2025-09-08",{"date":38,"type":39},"2025-09-09","ACTUAL",{"date":41,"type":39},"2023-05-18",{"date":43,"type":22},"2026-12",{"name":45,"class":46},"Epiliquid Holding, Inc","INDUSTRY",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":17,"minAge":57,"maxAge":19,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":47},"100605926","colon-cancer-liquid-biopsy-investigation-of-methylation-based-biomarkers-evaluation-using-delta-hld-climbed-100605926","NCT07168876","Colon Cancer Liquid Biopsy Investigation of Methylation-based Biomarkers Evaluation Using Delta-HLD (CLIMBED)","Clinical Validation Cross-sectional Study for Colorectal Cancer Assessment Using Delta-HLD Technology (CLIMBED)","CLIMBED","Inclusion Criteria:\n\n* Men and women aged 45-75 years\n* Indication of colorectal cancer screening colonoscopy by treating physician\n\nExclusion Criteria:\n\n* First-degree family history of CRC\n* Inflammatory bowel disease (ulcerative colitis, Crohn's disease)\n* Other malignancies within 5 years\n* Known hereditary CRC syndromes (Lynch, FAP)\n* Major trauma, surgery, transfusion in past 30 days\n* Current participation in an interventional clinical trial",true,"45 Years",{"count":59,"type":22},3200,"CLIMBED (Colon cancer Liquid biopsy Investigation of Methylation-based Biomarkers Evaluation using Delta-HLD) is a non-randomized, observational, cross-sectional clinical validation study designed to assess the performance of Delta-HLD, Epiliquid's proprietary liquid biopsy technology, for colorectal cancer (CRC) detection. The study will evaluate the test performance in an average-risk population for CRC undergoing screening colonoscopy, which will serve as the gold standard reference.",[62],"Colorectal Cancer (CRC)",[64,29,65,31,32,66,34],"Colorectal cancer","Liquid biopsy","Methylarion","2025-09-04",{"date":69,"type":39},"2025-09-11",{"date":71,"type":39},"2024-04-04",{"date":73,"type":22},"2028-12",{"name":45,"class":46},{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":19,"enrollmentInfo":83,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":95,"locationsCount":47},"100604344","colorectal-analysis-for-signature-cancer-assessment-using-delta-hld-100604344","NCT07148297","Colorectal Analysis for Signature Cancer Assessment Using Delta-HLD","Proof-of-concept Case-control Study for Colorectal Cancer Assessment Using Delta-HLD Technology (CASCADE)","CASCADE","Inclusion Criteria:\n\n* Candidate for colonoscopy or colorectal surgery\n* Willing and able to provide informed consent\n* Able to provide blood and\u002For tissue sample before treatment or resection\n\nExclusion Criteria:\n\n* Prior history of colorectal cancer\n* Inflammatory bowel disease\n* Known hereditary cancer syndromes (e.g., Lynch, FAP)\n* Other active malignancies\n* Recent chemotherapy or immunosuppressive treatment",{"count":84,"type":22},600,"CASCADE (Colorectal Analysis for Signature Cancer Assessment Using delta-HLD Technology) is a proof-of-concept case-control study designed to evaluate the performance of delta-HLD, Epiliquid's proprietary liquid biopsy technology, for the detection of colorectal cancer. Epiliquid also integrates a proprietary bioinformatic system capable of identifying, ranking, and selecting tumor-specific methylation biomarkers for different cancer types. In this study, colorectal cancer-specific biomarkers will be evaluated in blood and tissue samples using delta-HLD technology, which enables sensitive and multiplexed detection through PCR. Study results will support the validation of Epiliquid's integrated platform as a minimally invasive and accessible diagnostic solution for colorectal cancer.",[87],"Colo-rectal Cancer",[64,29,30,31,32,33,34],"2025-08-22",{"date":91,"type":39},"2025-08-29",{"date":93,"type":39},"2021-06-30",{"date":43,"type":22},{"name":45,"class":46},""]